Efficacy Measures: PFS, ORR, OS, & Subset Analyses

Efficacy Measures: PFS, ORR, OS, & Subset Analyses
THE AXIS TRIAL: A PHASE 3 TRIAL IN 2nd-LINE mRCC
A phase 3, multicenter, open-label, head-to-head trial vs sorafenib (N=723)
References
  1. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939.
  2. Data on file. Pfizer Inc, New York, NY.
  3. Motzer RJ, Escudier B, Tomczak P. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552-562.
  4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer V.2.2020. ©National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed November 13, 2019. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.
BAVENCIO is a trademark of Merck KGoA, Darmstadt, Germany. All other trademarks are property of their respective owners.